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INTRODUCTION 
In ocular drug delivery system, there is a main problem of 
rapid and extensive elimination of conventional eye drops 
from the eye. This problem results in extensive loss of 
drug. Only a few amount of drug penetrates the corneal 
layer and reached to internal tissue of eye. The main region 
of drug loss includes lachrymal drainage and drug dilution 
by tears. This superfluity reduces the ocular bioavailability 
and lead to unwanted toxicity and side effect. The 
following characteristics are required to optimize ocular 
drug delivery systems.  
 A good corneal penetration.  
 A prolonged contact time of drug with corneal tissue.  
 Simplicity of installation and removal for the patient.  
 A non-irritative and at ease form (the viscous solution 
should not irritate lachrymation and reflex flashing).  
 Appropriate rheological properties and concentration 
of viscolyzer.  
Over last two decades valuable attention is to be made on 
development of sustained and controlled release drug 
delivery system. The aim of such system based on 
localization on site of action so as to avoid the dose 
frequency and improvement in the drug effectiveness.1 
Advantages of controlled ocular drug delivery 
systems
2,78 
 Increased accurate dosing. To overcome the side 
effects of pulsed dosing produced by conventional 
systems. 
 To provide sustained and controlled drug delivery. 
 To increase the ocular bioavailability of drug by 
increasing the corneal contact time. This can be 
achieved by effective adherence to corneal surface. 
 To provide targeting within the ocular globe so as to 
prevent the loss to other ocular tissues. 
 To circumvent the protective barriers like drainage, 
lacrimation and conjunctive absorption. 
 To provide comfort, better compliance to the patient 
and to improve therapeutic performance of drug. 
 To provide better housing of delivery system2. 
 Easy convenience and needle free drug application 
without the need of trained personnel assistance for 
the application, self medication, thus improving 
patient compliances compared to parenteral routes. 
 Good penetration of hydrophilic, low molecular 
weight drugs can be obtained through the eye. 
 Rapid absorption and fast onset of action because of 
large absorption surface area and high vascularisation. 
Ocular administration of suitable drug would therefore 
be effective in emergency therapy as an alternative to 
other administration routes.  
 Avoidance of hepatic first pass metabolism and thus 
potential for dose reduction compared to oral 
delivery78. 
 
Disadvantages
78,79
  
Various disadvantages of ocular drug delivery system are 
given below. 
 The physiological restriction is the limited 
permeability of cornea resulting into low absorption of 
ophthalmic drugs. 
 A major portion of the administered dose drains into 
the lacrimal duct and thus can cause unwanted 
systemic side effects. 
 The rapid elimination of the drug through the eye 
blinking and tear flow results in a short duration of the 
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therapeutic effect resulting in a frequent dosing 
regimen78,79 
Physiological barriers of ophthalmic drug delivery 
systems
2 
 Physiological barriers to diffusion and productive 
absorption of topically applied drug exist in the 
precorneal and corneal spaces. The precorneal 
constraints responsible for poor ocular bioavailability 
of conventional ophthalmic dosage forms are solution 
drainage, lacrimation, tear dilution, tear turnover and 
conjunctival absorption. 
 Drug solution drainage away from the precorneal area 
has been shown to be the most significant factor in 
reducing the contact time of the drug with the cornea 
and consequently ocular bioavailability of topical 
dosage forms. 
 The instilled dose leaves the precorneal area within 2 
minutes of installation in humans. The ophthalmic 
dropper delivers 50‐ 75 μl, of the eye drops. If the 
patient does not blink, the eye can hold about 30 μl, 
without spilling on to the cheek. 
 The natural tendency of the cul‐de‐sac is to reduce its 
volume to 7‐10 μl. However, most of the drug is 
rapidly lost through nasolacrimal drainage 
immediately following dosing. The drainage allows 
the drug to be absorbed across the nasal mucosa into 
the systemic circulation. The conjunctiva also 
possesses a relatively large surface area, 5 times the 
surface of cornea making the loss significant. Both 
conjunctival and nasal mucosa has been indicated as 
the main potential sites for systemic absorption of 
topically applied drugs.  
 
Mechanism of controlled sustained drug release into 
the eye
2
 
 The corneal absorption represents the major 
mechanism of absorption for the most conventional 
ocular therapeutic entities. 
 Passive Diffusion is the major mechanism of 
absorption for nor‐erodible ocular insert with 
dispersed drug. 
 Controlled release can further regulated by gradual 
dissolution of solid dispersed drug within this matrix 
as a result of inward diffusion of aqueous solution.2 
ANATOMY AND FUNCTION OF THE EYE 
The eye is a spherical structure with a wall made up of 
three layers; the outer part sclera, the middle parts choroid 
layer, Ciliary body and iris and the inner section nervous 
tissue layer retina.  
The structure of the cornea
3,13 
The clear transparent bulge cornea situated at the front of 
the eye that conveys images to the back of the nervous 
system. The adult cornea has a radius of approximately 7-
8mm that covers about one-sixth of the total surface area 
of the eye ball that is a vascular tissue to which provides 
nutrient and oxygen are supplied via lachrymal fluid and 
aqueous humor as well as from blood vessels of the 
junction between the cornea and sclera in fig.1.
 
 
Figure 1: The structure of the eye3 
Conjunctiva
3,10 
The conjunctiva protects the eye and also involved in the 
formation and maintenance of the precorneal tear film. The 
conjunctiva is a thin transparent membrane lies in the inner 
surface of the eyelids and that is reflected onto the globe. 
The conjunctiva is made of an epithelium, a highly 
vascularised substantia propria, and a submucosa.  
Nasolachrymal drainage system
3 
Nasolachrymal drainage system consists of three parts; the 
secretory system, the distributive system and the excretory 
system. The secretory portion is composed of the lacrimal 
gland that secreted tears are spread over the ocular surface 
by the eyelids during blinking. The distributive system 
consists of the eyelids and the tear meniscus around the lid 
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edges of the open eye, which spread tears over the ocular 
surface by blinking, thus preventing dry areas from 
developing. The excretory part of the Nasolachrymal 
drainage system consists of the lachrymal puncta, the 
superior, inferior and common canaliculi; the lachrymal 
sac, and the nasochrymal duct.  
 
Figure 2: Schematic diagram of nasolachrymation 
drainage system3 
Tear film
3 
A thin fluid layer is covered the exposed part of the eye 
called as precorneal tear film. The film thickness is about 
3–10 Am depending on the measurement method with the 
resident volume approximately 10 μl. The osmolality of 
the tear fluid is approx. 310– 350 mOsm/kg in normal eyes 
and is maitained by the monovalent and divalent inorganic 
ions present in fluid such as Na+, K+, Cl-, HCO3-, and 
proteins. The mean pH of normal tears is about 7.4. 
Diurnal patterns of pH changes the pH of tear, which a 
general shift from acid to alkaline during the day. The 
buffer capacity of the tears fluid is determined by 
bicarbonate ions, proteins, and mucins . Tears exhibit a 
non-Newtonian rheological behaviour with viscosity is 
about 3m Pas 12 .The mean surface tension of tear film 
value is about 44 mN/m. 
SIGNIFICANCE OF MICROSPHERES IN OCULAR 
DRUG DELIVERY
5 
Even though the various drug delivery systems mentioned 
above offer numerous advantages over conventional drug 
therapy, nonetheless, they are not devoid of pitfalls, 
including 
 Poor patient compliance and difficulty of insertion for 
ocular inserts. 
 Tissue irritation and damage caused by penetration 
enhancers and collagen shields. 
Much of the published data suggests that in the case of 
ophthalmic drug delivery, an appropriate particle size and 
a narrow size range, ensuring low irritation, adequate 
bioavailability and compatibility with ocular tissues, 
should be sought for every suspended drug. Other 
formulation factors, that are the use of correct wetting, 
suspending and buffering agents, protective colloids, 
preservatives, and so on, should also be carefully 
considered. Thus, an optimum ocular drug delivery system 
should be one which can be delivered in the form of eye 
drops, causing no blurred vision or irritability and would 
need no more than one to two administrations per day. 
Various criteria that need to be considered, while deciding 
the formulation parameters for developing a suitable 
ophthalmic drug delivery system are shown in (Table 1). 
Though the delivery of drugs to the anterior segment of the 
eye is achieved mainly through topical delivery, very little 
of the topically applied drug reaches the posterior segment 
of the eye. This necessitates the administration of some 
drugs, such as antiglaucoma drugs, corticosteroids and 
certain antibiotics by the systemic route. However, a very 
small fraction of the dose reaches the ocular tissues, 
following systemic administration. The doses required to 
give a therapeutic effect via this route, however, can lead 
to considerable side effects. The use of nanotechnology-
based drug delivery systems like nanosuspensions, solid 
lipid nanoparticles, liposomes & microspheres has led to 
the solution of various solubility-related problems of 
poorly soluble drugs, like dexamethasone, budenoside, 
gancyclovir and so on.  
Drugs can also be targeted to mononuclear phagocyte 
systems to allow regional specific delivery and minimize 
side effects in other organs.Besides this, depending on 
their particle charge, surface properties and relative 
hydrophobicity, nanoparticles can be designed to be 
successfully used in overcoming retinal barriers. In 
addition to these points, encapsulation of drugs in 
nanospheres, liposomes, and so on, can also provide 
protection for the drug and hence prolong exposure of the 
drug by controlled release.  
Nanotechnology-based drug delivery is also very efficient 
in crossing membrane barriers, such as the blood retinal 
barrier in the eye. The drug delivery systems based on 
nanotechnology may prove to be the best drug delivery 
tools for some chronic ocular diseases, in which frequent 
drug administration is necessary, for example in 
ophthalmic diseases like chronic cytomegalovirus retinitis 
(CMV). In this disease, the topical delivery of drugs like 
ganciclovir (GCV) is prevented and intravitreal delivery is 
preferred. Though the half-life of GCV, following 
intravitreal administration, is 13 h, frequent injections are 
necessary to maintain therapeutic levels, since this drug 
prevents the replication of the viral deoxy ribononucleic 
acid (DNA), but does not eliminate the virus from the 
tissue.  
Therefore, long term therapy is necessary, which may 
result in cataract development, retinal detachment and 
endophthalmitis  GCV intravitreal implants can be used, 
which release drugs for six to eight months, but there can 
be issues, such as side effects like astigmatism and 
vitreous hemorrhage; moreover, the need for surgery to 
remove the implants seriously restricts their use. These 
difficulties can be overcome by using nanoparticles made 
up of various natural polymers like albumin, because of 
their smaller size and controlled release properties. When 
delivered to the eye, these nanoparticles did not induce 
inflammatory reactions in the retinal tissue or disturb the 
organization of the surrounding ocular tissues.  
Nanotechnology-based drug delivery is also suitable in the 
case of the retina, as it has no lymph system, hence retinal 
neovascularization and CNV have similar environments to 
that of solid tumors, in which the EPR effectmay be 
available for drug targeting by nanoparticles. The major 
problemof intravitreal injection is of inducing the 
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stimulation of pathogenic immune responses, resulting in 
photoreceptor degeneration. Various studies have also 
shown that intravitreal administration of nanoparticles did 
not generate organ-specific autoimmune phenomena.5
 
Table 1: Criteria for the selection of optimal formulation parameters when developing an ophthalmic drug delivery 
system
5 
Factor Preference 
Drug 
 
Preferentially lipophilic. Non-ionisable lipophilic compounds will concentrate into the corneal 
epithelium, while ionisable lipophilic ones will partitionate into the aqueous humor 
Vector type Depends on encapsulated molecule. Should allow a high loading dose to reduce the instilled volume 
Carrier size Lowest as possible to facilitate corneal uptake and passage 
Osmotic pressure Isotonic with physiological fluids to avoid irritation and lacrimation 
pH 
 
Close to physiological pH to avoid irritation and lacrimation. If buffering is necessary, the lowest 
possible buffer concentration is to be used (<0.1 M) 
 
 
Figure 3: Different delivery systems which are currently used for ocular therapy4 
MICROSPHERES IN OCULAR DELIVERY
6,14,17 
One of the main problems in ophthalmic drug delivery, the 
rapid elimination of conventional liquid eye drops from the 
eye, still remains unsolved. A number of factors, namely 
rapid tear turnover and the resulting precorneal loss, 
induction of tear flow due to irritation caused by the drug 
preparation, as well as the relatively large volume of the 
administered eye drop (-50 ~1 versus 7 ~1 of cornea1 tear 
film), lead to a high rate of lacrimal drainage. Due to the 
resulting elimination rate. the precorneal half life of drugs 
applied by these pharmaceutical formulations is considered 
to be between about 1-3 min. As a consequence, only the 
very small amount of about l-3% of the dosage actually 
penetrates through the cornea and is able to reach 
intraocular tissues.  
The poor productive absorption, on the other hand, results 
in a high amount of drug that is drained into the nose or 
into the gut. Especially the nose but also the gut are very 
efficient absorption organs of the body. This in turn leads 
to an extensive systemic absorption and may result in 
unwanted side effects and toxicity of the drug. Although 
these problems have been recognised for a long time, 
surprisingly little effort has been made by drug companies 
to improve the situation, and only very few alternative 
ocular drug delivery systems are on the market. One 
possibility for such systems is the employment of small 
particles. These colloidal particles have the advantage that 
they may be applied in liquid form just like eye drop 
solutions.  
Thus they avoid the discomfort that is combined with the 
application of viscous or sticky preparations such as 
ointments. The latter preparations lead to a total blurring of 
vision if they are properly utilised. Large inserts, on the 
other hand are difficult to administer or if they are 
designed as non-dissolving inserts they are even more 
difficult to remove, especially by elderly patients. Another 
alternative to small particle systems are liposomes. 
Liposomes. however. may have the disadvantage of lower 
stability. Suitable small particle systems include 
microspheres and microcapsules as well as nanoparticles 
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and nanocapsules. Microparticles and microcapsules have 
a particle size above 1μm.  
Microspheres are monolithic particles possessing a porous 
or solid polymer matrix, whereas microcapsules consist of 
a polymeric membrane surrounding a solid or liquid drug 
reservoir. Nanoparticles have a particle size in the 
nanometer size range below 1 μm. The definitions for 
these particles include nanospheres as well as 
nanocapsules. In micro- or in nanocapsules the drug can be 
present in a liquid form, it can be dissolved or suspended 
in a liquid or solid core or it may be present in the core 
itself. Monolithic micro- or nanoparticles contain the drug 
either dissolved in the polymer matrix in form of a solid 
solution or suspended in form of a solid dispersion. 
Alternatively the drug may be adsorbed to the particle 
surface. It is important to note that the particle size for 
ophthalmic applications should not exceed 10 μm because 
with larger sizes a scratching feeling might occur. 
Therefore, a reduction in particle size improves the patient 
comfort during administration6. 
MANUFACTURING METHODS OF OCULAR 
MICROSPHERES
6 
A large number of production methods exist for 
microspheres, microcapsules and nanoparticles. The 
optimal method that may be used for the preparation 
depends mainly on the drug to be used. Since the 
description and the discussion of the various production 
methods would by far exceed the space allocated to the 
present review, the reader who is interested in further 
details is referred to various books and reviews that 
extensively describe these topics.  
A high incorporation ratio, in combination with a 
considerable amount of free drug in order to obtain an 
adequate initial drug level, as well as a sustained drug 
release during the residence time of the carrier systems in 
the precorneal area` are required for ophthalmic use. So 
far, various synthetic and natural biocompatible polymers 
have been used in order to manufVF Gacture microspheres 
for ocular drug delivery (Table 2). Preparation techniques 
using natural biopolymers like albumin are summarised in 
Table 3.
Table 2:  Nano- and microparticulate carriers in ophthalmology 
Drug Polymer  Reference 
Amikacin 
Betaxolol 
 
 
 
Carteolol 
 
Chloram-
phenicol 
 
Hydro-cortisone 
 
Indomethacin 
 
Pilocarpine 
 
 
 
 
 
 
 
 
 
 
Progesterone 
 
 
Timolol 
Poly(butyl)cyanoacrylate 
Poly(epsilon)caprolacton 
Poly( isobutyl)cyanoacrylate 
Polylactic-co-glycolic acid 
 
Poly(epsilon)caprolacton 
 
Polylactic acid 
 
 
Albumin 
 
Poly(epsilon)caprolacton 
 
Albumin 
Cellulose-acetate-hydrogenphthalate 
Gelatine 
Poly(butyl)cyanoacrylate 
Poly( hexyl)cyanoacrylate 
Polylactic acid 
Poly(methyl)methacrylateacrylic-
acid- copolymer 
Poly(methyl)methacrylate 
Polyamide 
Polyphthalamide 
Poly(hexyl)cyanoacrylate 
Poly( butyl)cyanoacrylate 
 
Poly(alkyl)cyanoacrylate 
 
20 
21,22 
22,23 
22 
 
24 
 
25 
 
 
26 
 
27 
 
28,29,30,31,32 
33,34,35,36 
28 
37,38,39,40,41,42,43 
38,40,43 
44 
45,46,47,48,49,50,51,52,53,54,55 
 
38,40 
56 
57 
58 
59 
 
60 
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Table 3: Manufacturing techniques used for preparing 
micro- and nanospheres6 
Manufacturing process 
1. Denaturation or cross-linking of macromolecules 
in emulsion form 
2. Interfacial polymerisation 
3. Formation in an aerosol phase 
4. Desolvation 
5. ggregation by pH adjustment and heat treatment 
6. Formation of nanoparticles via microemulsions 
 
Polymer exhibits favorable biological behavior such as 
bioadhesion, permeability-enhancing properties, and 
interesting physico-chemical characteristics, which make it 
a unique material for the design of ocular drug delivery 
vehicles. Due to their elastic properties, polymer hydro 
gels offer better acceptability, with respect to solid or 
semisolid formulation, for ophthalmic delivery, such as 
suspensions or ointments, ophthalmic chitosan gels 
improve adhesion to the mucin, which coats the 
conjunctiva and the corneal surface of the eye, and 
increase precorneal drug residence times, showing down 
drug elimination by the lachrymal flow80,81. In addition, its 
penetration enhancement has more targeted effect and 
allows lower doses of the drugs.  
In contrast, polymer based colloidal system were found to 
work as transmucosal drug carriers, either facilitating the 
transport of drugs to the inner eye (chitosan-coated 
colloidal system containing indomethacin) or their 
accumulation into the corneal/conjunctival epithelia 
(chitosan nanoparticulate containing cyclosporine). The 
micro particulate drugcarrier (micro spheres) seems a 
promising means of topical administration of acyclovir to 
the eye. The duration of efficacy of the ofloxacin was 
increased by using high MW (1930 kd) 
chitosan80.Microspheres for ophthalmic drug delivery 
prepared from synthetic polymers (i.e. poly (alkyl) 
cyanoacrylates) have been mainly produced by emulsion 
polymerisation. In this process, a poorly soluble monomer 
is dissolved in the continuous phase. This continuous 
phase can be aqueous or organic. Additional monomer 
may be emulsified in emulsion droplets that are stabilized 
by emulsifiers.  
The polymerisation is started by chemical initiation, pH 
shift, or by irradiation with gamma-rays, ultraviolet (UV) 
or visible light. The location of the polymerisation is in the 
continuous phase where dissolved monomer molecules 
react with each other and grow until particle formation by 
phase separation occurs. Additional monomer molecules 
diffuse to the resulting growing polymer particles and 
maintain the polymerisation. The emulsion droplets mainly 
act as monomer reservoirs. In later stages, the emulsifiers 
stabilise the resulting polymer particles. It has to be noted, 
that the nanoparticles are not formed by one single 
polymer molecule but consist of a large number of 
macromolecules. Nanocapsules with an oily core were 
prepared mainly by the addition of benzylbenzoate or 
mineral oils.  
In this case, the polymerisation of the 
poly(alkyl)cyanoacrylates (i.e.poly(isobutyl) 
cyanoacrylate) is located at the interface between the oily 
and the aqueous phase resulting in a small capsule covered 
by a polymer membrane. As shown in Table 1, a number 
of studies deal with the preparation and application of 
ophthalmic drugs loaded to micro- and nanospheres. 
Pilocarpine is still among one of the most important drugs 
for ocular delivery and glaucoma therapy. Also, beta-
blockers like timolol and more recently betaxolol were 
investigated as potent candidates for particulate 
ophthalmic drug delivery systems. In most cases, the drug 
is present during the polymerisation- or particle 
manufacturing process leading to an incorporation of the 
drug in form of a solid solution or solid dispersion. 
Alternatively, a drug can be adsorbed onto the particle 
surface after the manufacturing process. In the case of 
hydrocortisone it was shown that a very high loading 
capacity can be reached. Similar results were observed for 
other steroids like progesterone. 
DRUG LOADING AND DRUG RELEASE 
KINETICS
19 
The active components are loaded over the microspheres 
principally using two methods, i.e. during the preparation 
of the microspheres or after the formation of the 
microspheres by incubating them with the drug/protein. 
The active component can be loaded by means of the 
physical entrapment, chemical linkage and surface 
adsorption. The entrapment largely depends on the method 
of preparation and nature of the drug or polymer 
(monomer if used). Maximum loading can be achieved by 
incorporating the drug during the time of preparation but it 
may get affected by many other process variables such as 
method of preparation, presence of additives (e.g. cross 
linking agent, surfactant stabilizers, etc.) heat of 
polymerization, agitation intensity, etc.  
Release of the active constituent is an important 
consideration in case of microspheres.The release profile 
from the microspheres depends on the nature of the 
polymer used in the preparation as well as on the nature of 
the active drug. The release of drug from both 
biodegradable as well as non-biodegradable microspheres 
is influenced by structure or micro-morphology of the 
carrier and the properties of the polymer itself. The drugs 
could be released through the microspheres by any of the 
three methods, first is the osmotically driven burst 
mechanism, second by pore diffusion mechanism, and 
third by erosion or the degradation of the polymer. In 
osmotically driven burst mechanism, water diffuse into the 
core through biodegradable or non-biodegradable coating, 
creating sufficient pressure that ruptures the membrane. 
The burst effect is mainly controlled by three factors the 
macromolecule/polymer ratio, particle size of the dispersed 
macromolecule and the particle size of the microspheres.  
The pore diffusion method is named so because as 
penetrating water front continue to diffuse towards the 
core. The polymer erosion, i.e. loss of polymer is 
accompanied by accumulation of the monomer in the 
release medium. The erosion of the polymer begins with 
the changes in the microstructure of the carrier as water 
penetrates within it leading to the plasticization of the 
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matrix. Drug release from the non-biodegradable type of 
polymers can be understood by considering the geometry 
of the carrier. The geometry of the carrier, i.e. whether it is 
reservoir type where the drug is present as core, or matrix 
type in which drug is dispersed throughout the carrier, 
governs overall release profile of the drug or active 
ingredients.
 
Table 4; Literature Related to Micro-and Nanoparticles Used in Ocular Drug Delivery
 
Drug  Prodrug Evaluation Remarks Ref.    
Vancomycin PLGA In vitro & in vivo 
studies 
In vitro studies revealed high encapsulation efficiency 
(84.2-99.5%) & increased AUC values(2 fold)of drug 
61 
Calcein  
 
Starch acetate In vivo studies Studies showed 82% viability of RPE culture cells when 
incubated with microparticles for 24 hrs 
62 
 
Colecoxib PLGA-PEG In vitro studies In vivo studies showed high loading efficiency(68.5%)of 
colecoxib in PLGA microparticles which inhibits diabetes 
induced retinal oxidative damage 
63 
Ketorolac NIPAAM, 
VP, AA 
In vitro studies Ocular bioavailability in cornea was enhanced upto 2 fold 
and studies showed high anti-inflammatory activity of 
ketorolac NP with no corneal damage 
 
64 
 
Cyclosporin A Chitosan In vitro & In vivo 
studies 
In vitro studies showed the fast release of CyA NP (293 
nm) during the first hr.then followed by a gradual released 
during a 24 hr period. In vivo studies showed high 
therapeutic concentration in ocular tissue 
65 
 
 
 
 
Acyclovir PEG-PECA Tolerance & 
Bioavailability studies 
Acyclovir loaded PEG coated (PECA) enhanced the drug 
level upto 25 fold in aqueous humour with better tolerance 
capacity 
66 
 
 
Rhodamine /Nile 
red 
Polylactide Ocular kinetics Studies shows steady and continuous delivery of drugs is 
achieved in the RPE 
67 
 
Ganciclovir Albumin Tolerance studies Well tolerated with no signs of inflammation in the retinal 
tissues (photoreceptor layer) 
68 
 
Fluorescein Chitosan In vitro & In vivo 
studies 
In vitro studies showed stablility of nanoparticles upon 
incubation with 
lysozyme & in vivo studies shows high amount of (Cs-fl) 
NP in corneal tissues as compared to Cs-fl solutions 
69 
 
 
 
 
Betamethasone 
phosphate 
Poly 
(lactic acid) 
In vivo studies Studies shows that NP controls the intraocular 
inflammation when administered systemically in EAU 
 
70 
 
LHRH agonist 
deslorelin 
and transferrin 
Polystyrene Surface modification  
 
Surface modification of NP by conjugating LHRH agonist 
provides a rapid & efficient delivery of NP into cornea and 
conjunctiva 
71 
 
 
Gatifloxacin Chitosan-Sodium 
Alginate 
In vitro studies In vitro studies shows the fast release of gatifloxacin 
nanoparticles during the first hr.followed by a more 
gradual release during a 24 hr.period 
72 
Dexamethasone 
Acetate 
PLGA In vitro & In vivo 
studies 
In vitro studies showed that drug was released in a 
controlled manner to treat CNV by inhibiting 
inflammatory responses 
73 
 
 
 
Indomethacin Chitosan Bioavailability 
Studies 
Studies showed a high level of drug in vivo as compared to 
solutions; so enhance the delivery to both external & 
internal ocular tissues 
74 
 
 
Dorzolamide & 
Pramipexole 
Chitosan In vitro studies In vitro studies shows sustained release of dorzolamide in 
PBS( pH 7.4) & pramipexole in SIF 
75 
 
Gene delivery 
(GFP,RFP) 
Chitosan. 
PCEP 
Transfection & 
toxicity studies 
PCEP & MNP nanoparticles are nontoxic and shows high 
transfection efficiency while MNP yields good 
transfection as compared to PCEP 
 
76 
 
Cyclosporin A Hyaluronic acid 
(PECA) 
In vitro studies In vitro studies shows HA coated PCL/BKC increased the 
level of CyA about 10-15 fold in cornea as compared to 
NP preparation in castor oil solution & PCL/BKC 
 
77 
 
 
Pilocarpine Albumin In vivo or in vitro 
studies 
-- 7 
 
RECENT STUDIES ON OPHTHALMIC DRUG DELIVERY SYSTEM USING MICROSHERES: 
Rathod et al. prepared egg albumin microspheres of 
pilocarpine nitrate by using the heat stabilization method. 
Factors that affect the size and encapsulation efficiency 
were optimized to obtain microspheres in the size range 1 
to 12 ìm to make them undetectable by eyes and sufficient 
to entrap drug efficiently. Encapsulation efficiency of egg 
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albumin microspheres was found to be that was to be 
63.4%. By using spherical matrix in vitro release of drug 
was evaluated. In the preparation of microsphere gel 
Carbopol–940 polymer was used. Comparative evaluations 
were made by preparing simple gels of same drug 
concentration. Bioavailability parameters of all the 
formulations were evaluated and comparisons were 
made78.  
Parmar et al. reported that mucoadhesive microspheres can 
be prepared by different methods and was evaluated for 
their mucoadhesive properties. The microsphere prepared 
by glutaraldehyde (as a crosslinking agent) and thermal 
cross linking showed good stability in HCl as compared 
with microsphere prepared by tripolyphosphate and 
emulsification ionotropic gelation method. In controlled 
and targeted drug delivery system, microspheres can be 
used because it overcomes the problems associated with 
conventional drug delivery like poor absorption, less 
contact time and poor bioavailability78. 
Giunchedi et al. studied that the poly (lactide-co-glycolide) 
(PLGA) microspheres serve as carriers for the topical 
ocular delivery of a peptide drug vancomycin. In this 
experiment microspheres were prepared by an 
emulsification/spray-drying technique that can be proposed 
as an alternative to the double emulsion method for 
preparation of peptide-loaded microparticles. The drug 
encapsulation efficiencies were evaluated that was close to 
the theoretical values (84.2–99.5%); the average particle 
size was about 11 mm. The microspheres were able to 
modulate the in vitro drug release of vancomycin with 
behaviour dependent on their composition: the highest 
drug content corresponded to the highest release rate. In 
vivo studies were carried out by determining the 
pharmacokinetic profile of VA in the aqueous humor of 
rabbits after topical administration of aqueous suspensions 
of microspheres. High and prolonged VA concentrations 
and increased AUC values (2-fold) with respect to an 
aqueous solution of the drug were observed. Increasing the 
viscosity of the microsphere suspension by addition of a 
suspending-viscosizing agent (hydroxy propyl cellulose) 
did not produce an increase of the ocular bioavailability. 
PLGA microspheres can be proposed as a system for 
ocular delivery of peptide drugs78. 
Giunchedi et al. evaluated the Pectin microspheres as 
ophthalmic carriers for piroxicam. In this they were 
prepared the microspheres by a spray-drying technique; 
their morphological characteristics were investigated by 
scanning electron microscopy (SEM) and their in vitro 
release behaviour was determined at pH 7.0 USP buffer 
using a flow-through apparatus. Px loaded in the pectin 
microspheres showed a faster in vitro dissolution rate with 
respect to solid micronized drug. The precorneal retention 
of fluorescein-loaded microspheres was evaluated in vivo 
in albino rabbits: an aqueous dispersion of fluorescent 
microspheres showed a significantly increased residence 
time in the eye (2.5 vs. 0.5 h) then fluorescein solution. 
Hence, concluded that increased bioavailability. In vivo 
tests in rabbits of dispersions of Px-loaded microspheres 
also indicated a significant improvement of Px 
bioavailability in the aqueous humour (2.5-fold) when 
compared with commercial Px eye drops78. 
Kreuter et al. reported that nanoparticles and microspheres 
provide the promising drug carriers for ophthalmic 
applications. The binding of drugs depends on the 
physicochemical properties of the drugs and polymer used, 
as well as of the nano and microparticle material and also 
on the manufacturing process for these particles. After 
optimal drug binding to these particles, the ocular 
bioavailability of a number of drugs is significantly 
enhanced in comparison to normal aqueous eye drop 
solutions as increased solubility. Generally, smaller 
particles are better tolerated by the patients than larger 
particles (no irritation). For this reason especially 
nanoparticles may be preferred for long-acting ocular drug 
delivery systems, although larger microparticles showed 
slower elimination kinetics from the precorneal 
compartment78. 
CONCLUSION 
Microspheres show promising drug carriers for ophthalmic 
applications.  The ocular bioavailability of a number of 
drugs is significantly enhanced in comparison to normal 
aqueous eye drop solutions. Generally, smaller particles 
are better tolerated by the patients than larger particles. For 
this reason especially microspheres may be preferred for 
long-acting ocular drug delivery systems, although larger 
microparticles showed slower elimination kinetics from 
the precorneal compartment. In future It has been found 
that ocular delivery based formulations have great 
applications for local treatment of eye disease with 
relatively lesser side effects as compared to other route of 
drug delivery.
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